IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 239 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.52 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $7,838,335 | -36.7% | 1,722,711 | -2.0% | 0.50% | -29.2% |
Q2 2023 | $12,381,665 | +17.1% | 1,758,759 | +1.7% | 0.70% | +17.2% |
Q1 2023 | $10,570,080 | -9.2% | 1,729,964 | -5.1% | 0.60% | -10.2% |
Q4 2022 | $11,643,091 | -15.2% | 1,822,080 | +27.1% | 0.67% | -16.2% |
Q3 2022 | $13,738,000 | -26.9% | 1,434,056 | -15.7% | 0.80% | -12.2% |
Q2 2022 | $18,781,000 | +4.0% | 1,701,191 | +56.8% | 0.91% | +26.1% |
Q1 2022 | $18,067,000 | +49.8% | 1,085,121 | +71.8% | 0.72% | +68.2% |
Q4 2021 | $12,061,000 | -43.3% | 631,784 | -26.7% | 0.43% | -45.5% |
Q3 2021 | $21,256,000 | -7.5% | 861,947 | -2.4% | 0.78% | -4.0% |
Q2 2021 | $22,986,000 | +2.8% | 883,395 | +25.1% | 0.82% | +12.2% |
Q1 2021 | $22,350,000 | -32.3% | 705,927 | -0.8% | 0.73% | -37.3% |
Q4 2020 | $33,009,000 | +35.5% | 711,398 | -3.8% | 1.16% | +18.5% |
Q3 2020 | $24,357,000 | +30.5% | 739,870 | +8.8% | 0.98% | +22.5% |
Q2 2020 | $18,664,000 | +37.8% | 679,937 | +50.3% | 0.80% | +5.8% |
Q1 2020 | $13,541,000 | – | 452,342 | – | 0.76% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Perceptive Advisors | 11,826,299 | $130,562,000 | 4.09% |
MPM BioImpact LLC | 1,200,000 | $13,248,000 | 3.68% |
Finepoint Capital LP | 960,200 | $10,601,000 | 3.66% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,011 | $273,000,000 | 2.85% |
Avoro Capital Advisors LLC | 9,220,000 | $101,789,000 | 2.01% |
Long Focus Capital Management, LLC | 1,625,000 | $17,940,000 | 1.88% |
683 Capital Management, LLC | 2,000,000 | $22,080,000 | 1.56% |
Parametrica Management Ltd | 115,870 | $1,268,000 | 1.38% |
Boxer Capital, LLC | 1,935,133 | $21,364,000 | 1.35% |
Soleus Capital Management, L.P. | 719,600 | $7,944,000 | 1.24% |